ACRS vs INCY
ACRS: A clinical-stage biopharmaceutical company developing targeted therapies for immuno-inflammatory diseases. INCY: Incyte is a biopharmaceutical company focused on discovering and developing innovative medicines for oncology and inflammatory conditions.
Side-by-side fundamentals
| Metric | ACRS | INCY | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $3.81 | $113.44 | |
| Market cap | $561M | $23.0B | |
| P/E as of 2026-10-21 | n/a | 16.02 | |
| Net margin FY2025, SEC XBRL | -829.6% | +25.0% | INCY higher |
| Operating margin FY2025, SEC XBRL | -975.9% | +29.5% | INCY higher |
| ROE FY2025, SEC XBRL | -63.0% | +24.9% | INCY higher |
| ROA FY2025, SEC XBRL | -40.5% | +18.5% | INCY higher |
| Revenue growth (YoY) FY2025, SEC XBRL | -58.2% | +21.2% | INCY higher |
| Revenue CAGR (3y) SEC XBRL | -35.9% | +14.8% | INCY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.06 | 0.54 | |
| 1-year return as of 2026-10-21 close | +60.1% | +29.9% | ACRS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.